Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956929 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1GAACPB1 | |
| SCHEMBL5956616 | 0.91 | ALDH1A1 (0.44) | ALDH1A1GAACPB1TSHRSIRT5 | |
| SCHEMBL5956620 | 0.91 | ALDH1A1 (0.44) | ALDH1A1GAACPB1TSHRSIRT5 | |
| SCHEMBL5956599 | 0.89 | MEN1 (0.46) | MEN1KMT2AALDH1A1GAACPB1 | |
| SCHEMBL5956606 | 0.89 | MEN1 (0.46) | MEN1KMT2AALDH1A1GAACPB1 | |
| SCHEMBL5956576 | 0.83 | KMT2A (0.55) | MEN1KMT2AALDH1A1GAACPB1 | |
| SCHEMBL5956772 | 0.83 | KMT2A (0.55) | MEN1KMT2AALDH1A1GAACPB1 | |
| SCHEMBL5956672 | 0.83 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1GAACPB1 | |
| SCHEMBL5956478 | 0.83 | KMT2A (0.55) | MEN1KMT2AALDH1A1GAACPB1 | |
| SCHEMBL5956680 | 0.83 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1GAACPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270570-B1 | AMIDE COMPOUNDS AND USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-6933305-B2 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-08-23 | — | — | US | disclosed |
| US-20030158413-A1 | Amide compounds and use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1270570-A1 | AMIDE COMPOUNDS AND USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158413-A1 | Amide compounds and use thereof | ROCK2, ROCK1, RHOT2 | MEN1 2543/4885KMT2A 1253/4885ALDH1A1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.